1. Pink Sheet
  2. >>Geography
  3. >>Europe

User Fee Conference Committee Targets Settling Differences In June

A conference committee tackles differences between House and Senate FDA user fee and agency reform bills, with an agreement expected before the end of June.

The House and Senate both avoided contentious issues in passing separate user fee bills with broad support, leaving questions about drug- and device-related fees for a conference committee to resolve. But the differences in H.R. 5651, the FDA Reform Act, and S. 3187, the FDA Safety and Innovation Act, could make it difficult for conferees to compromise within the deadline set by House and Senate leaders, who want to send the legislation to President Obama by the end of June. Below are differences in the bills’ drug-related provisions and possible outcomes of the conference process.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU Pharma Package: Keep Patients Front & Center In Defiing Unmet Medical Need

 
• By Francesca Bruce

EU trilogs on the new pharmaceutical legislation will finalize the role patients will take in influencing the development of a new definition of unmet medical need.

Defining Unmet Medical Need: EU Debate Sparks Concern Over Innovation And Access

 
• By Francesca Bruce

Revision of the EU’s pharmaceutical legislation will include a new definition of unmet need, but getting it wrong could have unintended consequences for pricing and reimbursement.

‘Urgent Need’ To Scale Up Advice Slots Under EU HTA Regulation – EUCOPE

 
• By Eliza Slawther

European regulators could investigate alternative ways of offering early advice to companies in relation to the Health Technology Assessment Regulation, given that official scientific advice slots are limited, a senior figure at EUCOPE says.

‘We Are Not The Dark Side Of The Force’ – EU Regulator Urges ATMP Firms To Use Advice Services

 
• By Eliza Slawther

While drug regulators are “conservative” by nature, the European Medicines Agency wants to help companies rather than rip their dossiers “into little pieces,” a senior regulatory assessor says.

More from Geography

Galderma’s Post Hoc Analysis Supports Nemluvio Claims But Clearer Disclosures Needed, NAD Says

 
• By Cathy Kelly

Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.

India’s R&D Financing Effort: Catalytic To De-Risking Early Innovation?

 
• By Anju Ghangurde

India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.

Defining Unmet Medical Need: EU Debate Sparks Concern Over Innovation And Access

 
• By Francesca Bruce

Revision of the EU’s pharmaceutical legislation will include a new definition of unmet need, but getting it wrong could have unintended consequences for pricing and reimbursement.